CN110201246A - 抗血栓形成移植物 - Google Patents

抗血栓形成移植物 Download PDF

Info

Publication number: CN110201246A
Authority: CN; China
Prior art keywords: decellularized; layer; tissue; coating; heparin
Prior art date: 2013-05-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN201910658935.1A

Other languages

English (en)

Chinese (zh)

Inventor

S·蒂米卓吾思嘉

L·尼克拉森

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Yale University

Original Assignee

Yale University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-20

Filing date

2014-05-19

Publication date

2019-09-06

2014-05-19 Application filed by Yale University filed Critical Yale University

2019-09-06 Publication of CN110201246A publication Critical patent/CN110201246A/zh

Status Pending legal-status Critical Current

Links

230000015572 biosynthetic process Effects 0.000 title abstract description 14
238000000576 coating method Methods 0.000 claims abstract description 144
239000011248 coating agent Substances 0.000 claims abstract description 121
238000000034 method Methods 0.000 claims abstract description 74
239000000203 mixture Substances 0.000 claims abstract description 73
210000004204 blood vessel Anatomy 0.000 claims abstract description 65
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 132
229920002674 hyaluronan Polymers 0.000 claims description 119
229960003160 hyaluronic acid Drugs 0.000 claims description 116
229920000669 heparin Polymers 0.000 claims description 101
229960002897 heparin Drugs 0.000 claims description 101
239000000758 substrate Substances 0.000 claims description 97
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 93
239000000017 hydrogel Substances 0.000 claims description 72
239000003146 anticoagulant agent Substances 0.000 claims description 71
230000002785 anti-thrombosis Effects 0.000 claims description 51
238000004132 cross linking Methods 0.000 claims description 48
229940127219 anticoagulant drug Drugs 0.000 claims description 20
238000011282 treatment Methods 0.000 abstract description 14
210000001519 tissue Anatomy 0.000 description 133
239000010410 layer Substances 0.000 description 122
230000002792 vascular Effects 0.000 description 82
239000000243 solution Substances 0.000 description 78
210000004027 cell Anatomy 0.000 description 77
210000000709 aorta Anatomy 0.000 description 58
241000700159 Rattus Species 0.000 description 54
210000000056 organ Anatomy 0.000 description 47
239000004971 Cross linker Substances 0.000 description 31
239000003431 cross linking reagent Substances 0.000 description 31
229920001223 polyethylene glycol Polymers 0.000 description 30
-1 N-[α-maleimidoacetoxy]succinimide ester Chemical class 0.000 description 28
239000000306 component Substances 0.000 description 23
239000000499 gel Substances 0.000 description 21
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
229920000642 polymer Polymers 0.000 description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
208000007536 Thrombosis Diseases 0.000 description 16
238000002513 implantation Methods 0.000 description 16
230000010412 perfusion Effects 0.000 description 16
108010035532 Collagen Proteins 0.000 description 15
102000008186 Collagen Human genes 0.000 description 15
229920001436 collagen Polymers 0.000 description 15
210000002889 endothelial cell Anatomy 0.000 description 15
239000000463 material Substances 0.000 description 15
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 14
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
239000003814 drug Substances 0.000 description 14
125000003277 amino group Chemical group 0.000 description 13
210000000702 aorta abdominal Anatomy 0.000 description 13
239000007943 implant Substances 0.000 description 13
239000011159 matrix material Substances 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 12
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 12
230000017531 blood circulation Effects 0.000 description 12
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
150000004676 glycans Chemical class 0.000 description 12
229920001282 polysaccharide Polymers 0.000 description 12
239000005017 polysaccharide Substances 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
239000000126 substance Substances 0.000 description 11
239000012620 biological material Substances 0.000 description 10
210000001715 carotid artery Anatomy 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
150000001875 compounds Chemical class 0.000 description 10
201000010099 disease Diseases 0.000 description 10
210000002744 extracellular matrix Anatomy 0.000 description 10
238000011534 incubation Methods 0.000 description 10
230000001732 thrombotic effect Effects 0.000 description 10
208000035475 disorder Diseases 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000003102 growth factor Substances 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
125000003396 thiol group Chemical group [H]S* 0.000 description 8
229950003937 tolonium Drugs 0.000 description 8
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 8
210000003462 vein Anatomy 0.000 description 8
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
108010014173 Factor X Proteins 0.000 description 7
230000000735 allogeneic effect Effects 0.000 description 7
125000000524 functional group Chemical group 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
238000006116 polymerization reaction Methods 0.000 description 7
230000001172 regenerating effect Effects 0.000 description 7
230000002885 thrombogenetic effect Effects 0.000 description 7
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 6
206010002329 Aneurysm Diseases 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
229940024606 amino acid Drugs 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
229920001222 biopolymer Polymers 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
239000003599 detergent Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
238000011084 recovery Methods 0.000 description 6
238000010186 staining Methods 0.000 description 6
229920001059 synthetic polymer Polymers 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
241000282465 Canis Species 0.000 description 5
229920002307 Dextran Polymers 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
239000007987 MES buffer Substances 0.000 description 5
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 5
208000018262 Peripheral vascular disease Diseases 0.000 description 5
210000001367 artery Anatomy 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
230000035602 clotting Effects 0.000 description 5
230000007547 defect Effects 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000001631 haemodialysis Methods 0.000 description 5
230000000322 hemodialysis Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
230000008569 process Effects 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000004044 response Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
FPKVOQKZMBDBKP-UHFFFAOYSA-N 1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 FPKVOQKZMBDBKP-UHFFFAOYSA-N 0.000 description 4
102000029816 Collagenase Human genes 0.000 description 4
108060005980 Collagenase Proteins 0.000 description 4
206010016717 Fistula Diseases 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000001588 bifunctional effect Effects 0.000 description 4
239000000560 biocompatible material Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
235000012754 curcumin Nutrition 0.000 description 4
VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
230000003890 fistula Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000005556 hormone Substances 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
238000010899 nucleation Methods 0.000 description 4
229920001451 polypropylene glycol Polymers 0.000 description 4
239000012744 reinforcing agent Substances 0.000 description 4
238000001878 scanning electron micrograph Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
CBYYPIYKJZCKGK-UHFFFAOYSA-N 2-(4-azidophenyl)-2-oxoacetaldehyde;hydrate Chemical compound O.[N-]=[N+]=NC1=CC=C(C(=O)C=O)C=C1 CBYYPIYKJZCKGK-UHFFFAOYSA-N 0.000 description 3
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
201000001320 Atherosclerosis Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
108010067306 Fibronectins Proteins 0.000 description 3
102000016359 Fibronectins Human genes 0.000 description 3
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 3
230000003872 anastomosis Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
229920000249 biocompatible polymer Polymers 0.000 description 3
VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000021164 cell adhesion Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
210000002808 connective tissue Anatomy 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
235000015872 dietary supplement Nutrition 0.000 description 3
230000004069 differentiation Effects 0.000 description 3
239000000975 dye Substances 0.000 description 3
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229940099552 hyaluronan Drugs 0.000 description 3
150000003949 imides Chemical class 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
KQYWQOXTZUHYEF-UHFFFAOYSA-N octanedioic acid;pyrrolidine-2,5-dione Chemical compound O=C1CCC(=O)N1.O=C1CCC(=O)N1.OC(=O)CCCCCCC(O)=O KQYWQOXTZUHYEF-UHFFFAOYSA-N 0.000 description 3
150000002924 oxiranes Chemical class 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
150000003141 primary amines Chemical group 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
229940125723 sedative agent Drugs 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
241000894007 species Species 0.000 description 3
210000003606 umbilical vein Anatomy 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
ZIUSSTSXXLLKKK-KOBPDPAPSA-N (1e,4z,6e)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 ZIUSSTSXXLLKKK-KOBPDPAPSA-N 0.000 description 2
OYKPJMYWPYIXGG-UHFFFAOYSA-N 2,2-dimethylbutane;prop-2-enoic acid Chemical compound OC(=O)C=C.OC(=O)C=C.OC(=O)C=C.CCC(C)(C)C OYKPJMYWPYIXGG-UHFFFAOYSA-N 0.000 description 2
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 2
ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 2
QQZOUYFHWKTGEY-UHFFFAOYSA-N 4-azido-n-[2-[2-[(4-azido-2-hydroxybenzoyl)amino]ethyldisulfanyl]ethyl]-2-hydroxybenzamide Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)NCCSSCCNC(=O)C1=CC=C(N=[N+]=[N-])C=C1O QQZOUYFHWKTGEY-UHFFFAOYSA-N 0.000 description 2
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
229920001661 Chitosan Polymers 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
229940123900 Direct thrombin inhibitor Drugs 0.000 description 2
102000016942 Elastin Human genes 0.000 description 2
108010014258 Elastin Proteins 0.000 description 2
241000283086 Equidae Species 0.000 description 2
229940123583 Factor Xa inhibitor Drugs 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
102000007625 Hirudins Human genes 0.000 description 2
108010007267 Hirudins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010003272 Hyaluronate lyase Proteins 0.000 description 2
102000001974 Hyaluronidases Human genes 0.000 description 2
102000007547 Laminin Human genes 0.000 description 2
108010085895 Laminin Proteins 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
108010009711 Phalloidine Proteins 0.000 description 2
229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
239000004365 Protease Substances 0.000 description 2
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
102000008790 VE-cadherin Human genes 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000013019 agitation Methods 0.000 description 2
229940072056 alginate Drugs 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
238000005576 amination reaction Methods 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229910001870 ammonium persulfate Inorganic materials 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940124599 anti-inflammatory drug Drugs 0.000 description 2
238000005452 bending Methods 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
238000006065 biodegradation reaction Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
108010018828 cadherin 5 Proteins 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229940045110 chitosan Drugs 0.000 description 2
229960005188 collagen Drugs 0.000 description 2
239000002131 composite material Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229920006037 cross link polymer Polymers 0.000 description 2
238000012258 culturing Methods 0.000 description 2
239000004148 curcumin Substances 0.000 description 2
229940109262 curcumin Drugs 0.000 description 2
230000008021 deposition Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
229920002549 elastin Polymers 0.000 description 2
238000012869 ethanol precipitation Methods 0.000 description 2
CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical group Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229960002989 glutamic acid Drugs 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
229960002773 hyaluronidase Drugs 0.000 description 2
239000000819 hypertonic solution Substances 0.000 description 2
229940021223 hypertonic solution Drugs 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000009545 invasion Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
229920001277 pectin Polymers 0.000 description 2
235000010987 pectin Nutrition 0.000 description 2
239000001814 pectin Substances 0.000 description 2
229960000292 pectin Drugs 0.000 description 2
229920001983 poloxamer Polymers 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
229920002627 poly(phosphazenes) Polymers 0.000 description 2
229920000058 polyacrylate Polymers 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
229920000193 polymethacrylate Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000031915 positive regulation of coagulation Effects 0.000 description 2
210000001147 pulmonary artery Anatomy 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
239000012465 retentate Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000003752 saphenous vein Anatomy 0.000 description 2
238000004626 scanning electron microscopy Methods 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000003868 thrombin inhibitor Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
238000012285 ultrasound imaging Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
229940019333 vitamin k antagonists Drugs 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108020004491 Antisense DNA Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003226 Arteriovenous fistula Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
102100030009 Azurocidin Human genes 0.000 description 1
101710154607 Azurocidin Proteins 0.000 description 1
108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 1
102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 1
102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
101150021185 FGF gene Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
101100462438 Mus musculus Otulin gene Proteins 0.000 description 1
108091005975 Myofilaments Proteins 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000035092 Neutral proteases Human genes 0.000 description 1
108091005507 Neutral proteases Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
235000004522 Pentaglottis sempervirens Nutrition 0.000 description 1
240000004050 Pentaglottis sempervirens Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010081750 Reticulin Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000002365 anti-tubercular Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229940075522 antidotes Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
229960005475 antiinfective agent Drugs 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940125716 antipyretic agent Drugs 0.000 description 1
239000003816 antisense DNA Substances 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
239000002473 artificial blood Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
239000000981 basic dye Substances 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
239000002442 collagenase inhibitor Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000000942 confocal micrograph Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
229940119679 deoxyribonucleases Drugs 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
125000004386 diacrylate group Chemical group 0.000 description 1
230000010339 dilation Effects 0.000 description 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
229940066493 expectorants Drugs 0.000 description 1
108060002895 fibrillin Proteins 0.000 description 1
102000013370 fibrillin Human genes 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
238000001879 gelation Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
230000000762 glandular Effects 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
230000012010 growth Effects 0.000 description 1
229920000591 gum Polymers 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
229940036998 hypertonic sodium chloride Drugs 0.000 description 1
210000003090 iliac artery Anatomy 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000007794 irritation Effects 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
238000002350 laparotomy Methods 0.000 description 1
239000008141 laxative Substances 0.000 description 1
229940125722 laxative agent Drugs 0.000 description 1
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000001349 mammary artery Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
210000003632 microfilament Anatomy 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000004660 morphological change Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000001048 orange dye Substances 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
230000003534 oscillatory effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000000734 parasympathomimetic agent Substances 0.000 description 1
230000001499 parasympathomimetic effect Effects 0.000 description 1
229940005542 parasympathomimetics Drugs 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
102000014187 peptide receptors Human genes 0.000 description 1
108010011903 peptide receptors Proteins 0.000 description 1
230000009984 peri-natal effect Effects 0.000 description 1
210000003516 pericardium Anatomy 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
229940070017 potassium supplement Drugs 0.000 description 1
230000037452 priming Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
210000003492 pulmonary vein Anatomy 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
210000002321 radial artery Anatomy 0.000 description 1
230000000637 radiosensitizating effect Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
238000001338 self-assembly Methods 0.000 description 1
235000004400 serine Nutrition 0.000 description 1
235000021309 simple sugar Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
235000008521 threonine Nutrition 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
210000002465 tibial artery Anatomy 0.000 description 1
239000010936 titanium Substances 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0064—Hydrogels or hydrocolloids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/08—Polysaccharides
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D7/00—Processes, other than flocking, specially adapted for applying liquids or other fluent materials to particular surfaces or for applying particular liquids or other fluent materials
- B05D7/50—Multilayers
- B05D7/52—Two layers
- B05D7/54—No clear coat specified
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
- C09D105/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D105/00—Coating compositions based on polysaccharides or on their derivatives, not provided for in groups C09D101/00 or C09D103/00
- C09D105/10—Heparin; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Dermatology (AREA)
Materials Engineering (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Surgery (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Dispersion Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Botany (AREA)
Pharmacology & Pharmacy (AREA)
Polymers & Plastics (AREA)
Biochemistry (AREA)
Materials For Medical Uses (AREA)
Prostheses (AREA)

CN201910658935.1A 2013-05-20 2014-05-19 抗血栓形成移植物 Pending CN110201246A (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361825256P	2013-05-20	2013-05-20
US61/825,256		2013-05-20
CN201480029024.8A CN105228665A (zh)	2013-05-20	2014-05-19	抗血栓形成移植物

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN201480029024.8A Division CN105228665A (zh)	2013-05-20	2014-05-19	抗血栓形成移植物

Publications (1)

Publication Number	Publication Date
CN110201246A true CN110201246A (zh)	2019-09-06

Family

ID=51934323

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN201910658935.1A Pending CN110201246A (zh)	2013-05-20	2014-05-19	抗血栓形成移植物
CN201480029024.8A Pending CN105228665A (zh)	2013-05-20	2014-05-19	抗血栓形成移植物

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CN201480029024.8A Pending CN105228665A (zh)	2013-05-20	2014-05-19	抗血栓形成移植物

Country Status (9)

Country	Link
US (2)	US9981066B2 (fr)
EP (1)	EP2999494B1 (fr)
CN (2)	CN110201246A (fr)
AU (2)	AU2014268778B2 (fr)
CA (1)	CA2912664C (fr)
DK (1)	DK2999494T3 (fr)
ES (1)	ES2829412T3 (fr)
HK (1)	HK1219242A1 (fr)
WO (1)	WO2014189835A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110732041A (zh) *	2019-10-12	2020-01-31	广东省人民医院(广东省医学科学院)	一种脱细胞小口径血管支架及其制备方法
CN115109293A (zh) *	2022-07-26	2022-09-27	浙江硕华生命科学研究股份有限公司	一种血沉试验管及其制备方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014189835A2 (fr) *	2013-05-20	2014-11-27	Yale University	Greffons anti-thrombose
WO2016154070A1 (fr)	2015-03-20	2016-09-29	William Marsh Rice University	Bioimpression hypothermique en 3d de tissus vivants supportée par un système vasculaire pouvant être perfusé
AU2016248234B2 (en)	2015-04-16	2020-07-02	Hollister Incorporated	Hydrophilic coatings and methods of forming the same
US12551509B2 (en)	2015-11-18	2026-02-17	Lucina Patent Holdco, Llc	Acellular regenerative products and methods of their manufacture
EP3448310B1 (fr)	2016-04-27	2024-07-31	Yale University	Compositions et procédés pour greffons modifiés avec une matrice extracellulaire dérivée de cellules non thrombogènes et promigratoires
CN106267369B (zh) *	2016-08-05	2019-05-31	华中科技大学同济医学院附属协和医院	一种人造血管及其制备方法
CN107412865A (zh) *	2016-10-27	2017-12-01	浙江保尔曼生物科技有限公司	高强度的具有抗凝血功能的去细胞化肾脏生物支架及制备方法
US11628239B2 (en) *	2016-11-04	2023-04-18	University Of Delaware	Method for protecting skeletonized blood vessels
WO2019006430A1 (fr) *	2017-06-30	2019-01-03	Vascudyne Inc	Implants en tissu régénératif et en tissu naturel
WO2019075213A1 (fr)	2017-10-11	2019-04-18	Northwestern University	Héparine conjuguée à des peptides se liant au collagène pour cibler des tissus biologiques et synthétiques
US12186452B2 (en)	2017-10-23	2025-01-07	Yale University	Compositions and methods useful in regenerative medicine
JP7418363B2 (ja)	2018-06-21	2024-01-19	イエールユニバーシティ	バイオ人工血管膵臓
IL280610B2 (en) *	2018-08-31	2024-08-01	Wisconsin Alumni Res Found	Fabrication of vascular grafts seeded with arterial endothelial cells
EP3846867B1 (fr)	2018-09-06	2025-02-19	Biomodics APS	Dispositif tubulaire médical
EP3927385A1 (fr) *	2019-02-19	2021-12-29	Tc1 Llc	Greffon vasculaire et procédés de scellement d'un greffon vasculaire
CN110354311A (zh) *	2019-08-30	2019-10-22	青岛大学	细胞外基质复合透明质酸凝胶及其制备方法、应用和生物材料
WO2021113584A1 (fr) *	2019-12-04	2021-06-10	Yale University	Greffons vasculaires de génie tissulaire ayant une résistance mécanique avancée
WO2023086925A1 (fr) *	2021-11-15	2023-05-19	The Texas A&M University System	Greffons vasculaires acellulaires anticoagulants et méthodes associées
CN115920130B (zh) *	2022-12-29	2024-07-16	季华实验室	基于prp活化剂-肝素处理的血管材料及其制备方法
CN116271251B (zh) *	2023-03-22	2024-12-10	中国人民解放军陆军军医大学	一种组织工程小口径人工血管移植物及其制备方法和应用
US20240408286A1 (en) *	2023-06-08	2024-12-12	Becton, Dickinson And Company	Tissue-plasminogen activator coated catheter with hydrogel-controlled elution
PL446936A1 (pl) *	2023-11-30	2024-10-21	Uniwersytet Mikołaja Kopernika W Toruniu	Proteza do odprowadzenia moczu u pacjentów pozbawionych pęcherza moczowego oraz sposób jej wytwarzania

Citations (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010044654A1 (en) *	2000-04-28	2001-11-22	Changyi Chen	Decellularized vascular prostheses resistant to thrombus occlusion and immunologic rejection
US20030048796A1 (en) *	2000-11-24	2003-03-13	Toshiyasu Yabe	Relay device
US20030161938A1 (en) *	2002-02-22	2003-08-28	Bo Johnson	Composition and method for coating medical devices
CN1455687A (zh) *	2000-10-24	2003-11-12	韩国美大富历寿株式会社	疏水性多组分肝素结合物,其制备方法及其应用
US20040038934A1 (en) *	2001-02-22	2004-02-26	Anika Therapeutics, Inc.	Thiol-modified hyaluronan
CN101066477A (zh) *	2007-05-17	2007-11-07	中国人民解放军第三军医大学	能在体捕获内皮祖细胞的生物人工血管
CN101249285A (zh) *	2007-02-21	2008-08-27	科迪斯公司	用于具有抗血栓形成共轭物的医疗装置的涂层
CN101703813A (zh) *	2009-11-25	2010-05-12	南开大学	利用内源性no供体构建抗凝血性血管支架材料的方法
CN101745327A (zh) *	2009-12-29	2010-06-23	浙江大学	一种在聚合物微孔膜表面固定生物分子的方法
US20130023507A1 (en) *	2004-04-30	2013-01-24	Advanced Cardiovascular Systems, Inc.	Hyaluronic acid based copolymers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030187515A1 (en) *	2002-03-26	2003-10-02	Hariri Robert J.	Collagen biofabric and methods of preparing and using the collagen biofabric
ES2548518T3 (es) *	2005-11-23	2015-10-19	Ventana Medical Systems, Inc.	Conjugado molecular
WO2014189835A2 (fr) *	2013-05-20	2014-11-27	Yale University	Greffons anti-thrombose

2014
- 2014-05-19 WO PCT/US2014/038597 patent/WO2014189835A2/fr not_active Ceased
- 2014-05-19 CN CN201910658935.1A patent/CN110201246A/zh active Pending
- 2014-05-19 CA CA2912664A patent/CA2912664C/fr active Active
- 2014-05-19 DK DK14800261.1T patent/DK2999494T3/da active
- 2014-05-19 EP EP14800261.1A patent/EP2999494B1/fr active Active
- 2014-05-19 US US14/783,897 patent/US9981066B2/en active Active
- 2014-05-19 CN CN201480029024.8A patent/CN105228665A/zh active Pending
- 2014-05-19 HK HK16107327.1A patent/HK1219242A1/zh unknown
- 2014-05-19 AU AU2014268778A patent/AU2014268778B2/en active Active
- 2014-05-19 ES ES14800261T patent/ES2829412T3/es active Active
2018
- 2018-04-26 US US15/963,750 patent/US20180243482A1/en not_active Abandoned
- 2018-11-29 AU AU2018271341A patent/AU2018271341B2/en active Active

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010044654A1 (en) *	2000-04-28	2001-11-22	Changyi Chen	Decellularized vascular prostheses resistant to thrombus occlusion and immunologic rejection
CN1455687A (zh) *	2000-10-24	2003-11-12	韩国美大富历寿株式会社	疏水性多组分肝素结合物,其制备方法及其应用
US20030048796A1 (en) *	2000-11-24	2003-03-13	Toshiyasu Yabe	Relay device
US20040038934A1 (en) *	2001-02-22	2004-02-26	Anika Therapeutics, Inc.	Thiol-modified hyaluronan
US6884788B2 (en) *	2001-02-22	2005-04-26	Anika Therapeutics, Inc.	Thiol-modified hyaluronan
US20030161938A1 (en) *	2002-02-22	2003-08-28	Bo Johnson	Composition and method for coating medical devices
US20130023507A1 (en) *	2004-04-30	2013-01-24	Advanced Cardiovascular Systems, Inc.	Hyaluronic acid based copolymers
CN101249285A (zh) *	2007-02-21	2008-08-27	科迪斯公司	用于具有抗血栓形成共轭物的医疗装置的涂层
CN101066477A (zh) *	2007-05-17	2007-11-07	中国人民解放军第三军医大学	能在体捕获内皮祖细胞的生物人工血管
CN101703813A (zh) *	2009-11-25	2010-05-12	南开大学	利用内源性no供体构建抗凝血性血管支架材料的方法
CN101745327A (zh) *	2009-12-29	2010-06-23	浙江大学	一种在聚合物微孔膜表面固定生物分子的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAN LIAO等: "Covalent linkage of heparin provides a stable anti-coagulation surface of decellularized porcine arteries", 《J. CELL. MOL. MED.》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN110732041A (zh) *	2019-10-12	2020-01-31	广东省人民医院(广东省医学科学院)	一种脱细胞小口径血管支架及其制备方法
CN115109293A (zh) *	2022-07-26	2022-09-27	浙江硕华生命科学研究股份有限公司	一种血沉试验管及其制备方法
CN115109293B (zh) *	2022-07-26	2023-10-27	浙江硕华生命科学研究股份有限公司	一种血沉试验管及其制备方法

Also Published As

Publication number	Publication date
DK2999494T3 (da)	2020-09-28
WO2014189835A2 (fr)	2014-11-27
EP2999494A2 (fr)	2016-03-30
HK1219242A1 (zh)	2017-03-31
AU2018271341B2 (en)	2020-09-03
ES2829412T3 (es)	2021-05-31
CA2912664C (fr)	2022-07-26
AU2018271341A1 (en)	2018-12-20
CN105228665A (zh)	2016-01-06
CA2912664A1 (fr)	2014-11-27
WO2014189835A3 (fr)	2015-02-26
EP2999494A4 (fr)	2017-01-18
AU2014268778B2 (en)	2018-09-20
US20160058913A1 (en)	2016-03-03
AU2014268778A1 (en)	2015-11-12
US9981066B2 (en)	2018-05-29
US20180243482A1 (en)	2018-08-30
EP2999494B1 (fr)	2020-09-16

Legal Events

Date	Code	Title	Description
2019-09-06	PB01	Publication
2019-09-06	PB01	Publication
2019-10-08	SE01	Entry into force of request for substantive examination
2019-10-08	SE01	Entry into force of request for substantive examination
2022-03-25	WD01	Invention patent application deemed withdrawn after publication
2022-03-25	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20190906

Publication	Publication Date	Title
AU2018271341B2 (en)	2020-09-03	Anti-thrombogenic grafts
Williams	2017	Biocompatibility pathways: biomaterials-induced sterile inflammation, mechanotransduction, and principles of biocompatibility control
US8883964B2 (en)	2014-11-11	Compositions comprising modified collagen and uses therefor
Wang et al.	2003	Crosslinked collagen/chitosan matrix for artificial livers
AU2001255741B2 (en)	2005-08-04	Decellularized vascular prostheses
Zhang et al.	2015	Application of hydrogels in heart valve tissue engineering
CN114377204A (zh)	2022-04-22	生物可消化性覆盖物及其应用
Liu et al.	2022	Development of a decellularized human amniotic membrane-based electrospun vascular graft capable of rapid remodeling for small-diameter vascular applications
US20090136553A1 (en)	2009-05-28	Triggerably dissolvable hollow fibers for controlled delivery
Wang et al.	2023	Developing small-diameter vascular grafts with human amniotic membrane: long-term evaluation of transplantation outcomes in a small animal model
Jiang et al.	2023	Hydrogel coating based on dopamine-modified hyaluronic acid and gelatin with spatiotemporal drug release capacity for quick endothelialization and long-term anticoagulation
Rashid et al.	2004	Cellular Engineering of Conduits for Coronary and Lower Limb Bypass Surgery: Role of Cell Attachment Peptides and Pre-conditioning in Optimising Smooth Muscle Cells (SMC) Adherence to Compliant Poly (carbonate–urea) urethane (MyoLink™) Scaffolds
CN115105631B (zh)	2023-03-14	一种冷浇注法制备的光聚合人工外泌体血管、其制备方法及应用
Wang et al.	2019	Regeneration of a neoartery through a completely autologous acellular conduit in a minipig model: a pilot study
Cheng et al.	2024	Development of heparinized and hepatocyte growth factor‐coated acellular scaffolds using porcine carotid arteries
Zhou et al.	2024	Transition from procoagulation to antiplatelet effect: application and mechanism of aspirin-modified chitosan in small-diameter vascular grafts
US11160906B2 (en)	2021-11-02	Injectable nanomaterial-extracellular matrix constructs
Shah et al.	2023	Bioactive sutures: advances in surgical suture functionalization
CN114225115B (zh)	2023-03-17	无损修饰的含有活细胞的血管替代物及制备方法
Valencia-Rivero et al.	2019	Evaluation of microscopic Structure− Function relationships of PEGylated small intestinal submucosa vascular grafts for arteriovenous connection
Armen	2022	Biomaterials: From Scaffold Design to Implant Optimization
Browning	2013	Development of Multilayer Vascular Grafts Based on Collagen-Mimetic Hydrogels
Habermehl	2005	Development and validation of a collagen-based scaffold for vascular tissue engineering
JP2003135586A (ja)	2003-05-13	細胞移植用担体及びこれを用いた細胞移植用材料
Dudash	2013	Cell selective endothelialization of biomimetic materials for modifying small diameter vascular grafts